Shelf-stable vaccine patch maker Vaxess Technologies announced today that it received an additional $9 million in funding.

A retrospective study found that women who took a GLP-1 drug for obesity were more likely to be diagnosed with acne vulgaris ...

The following is a summary of “Efficacy of 12 months therapy with glucagon-like peptide-1 receptor agonists liraglutide and ...

In people with type 2 diabetes, both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 ...

To prevent muscle loss, more physicians are emphasizing the importance of fat loss vs weight loss for patients taking GLP-1 ...

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

A real-world study finds cardiovascular and survival benefits from dual therapy in patients with type 2 diabetes.

A new paper by the Institute for Clinical and Economic Review (ICER) looks at the cost-effectiveness versus affordability issue of obesity medications such as Wegovy and Zepbound.

Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

A new study published in the Journal of American Medical Association showed that glucagon-like peptide-1 receptor agonists ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...